Oxford Immunotec Global PLC (NASDAQ:OXFD) Director Richard A. Sandberg sold 12,000 shares of the stock in a transaction that occurred on Tuesday, November 8th. The shares were sold at an average price of $14.17, for a total transaction of $170,040.00. Following the completion of the transaction, the director now owns 31,774 shares in the company, valued at $450,237.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) opened at 14.18 on Friday. The firm’s market capitalization is $320.50 million. The firm has a 50-day moving average of $13.02 and a 200 day moving average of $10.53. Oxford Immunotec Global PLC has a 12-month low of $7.73 and a 12-month high of $14.72.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last announced its quarterly earnings results on Tuesday, November 1st. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.15. The company had revenue of $26.10 million for the quarter, compared to analyst estimates of $24.79 million. Oxford Immunotec Global PLC had a negative net margin of 30.17% and a negative return on equity of 28.36%. The firm’s revenue was up 45.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.20) EPS. On average, equities research analysts expect that Oxford Immunotec Global PLC will post ($1.16) earnings per share for the current year.

OXFD has been the topic of several analyst reports. TheStreet upgraded shares of Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a report on Friday, September 30th. Zacks Investment Research upgraded shares of Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a report on Thursday, August 11th. Finally, BTIG Research reiterated a “buy” rating and issued a $17.00 target price on shares of Oxford Immunotec Global PLC in a report on Tuesday, August 2nd.

Several large investors have recently made changes to their positions in OXFD. Rhumbline Advisers raised its stake in shares of Oxford Immunotec Global PLC by 31.9% in the second quarter. Rhumbline Advisers now owns 24,180 shares of the company’s stock valued at $218,000 after buying an additional 5,850 shares during the period. Teachers Advisors Inc. raised its stake in shares of Oxford Immunotec Global PLC by 13.7% in the second quarter. Teachers Advisors Inc. now owns 33,382 shares of the company’s stock valued at $300,000 after buying an additional 4,021 shares during the period. American International Group Inc. raised its stake in shares of Oxford Immunotec Global PLC by 8.3% in the second quarter. American International Group Inc. now owns 12,779 shares of the company’s stock valued at $115,000 after buying an additional 982 shares during the period. BlackRock Institutional Trust Company N.A. raised its stake in shares of Oxford Immunotec Global PLC by 6.5% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 178,919 shares of the company’s stock valued at $1,610,000 after buying an additional 10,948 shares during the period. Finally, BlackRock Fund Advisors raised its stake in shares of Oxford Immunotec Global PLC by 9.3% in the second quarter. BlackRock Fund Advisors now owns 574,157 shares of the company’s stock valued at $5,167,000 after buying an additional 48,964 shares during the period. 76.49% of the stock is currently owned by institutional investors.

Oxford Immunotec Global PLC Company Profile

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions.

5 Day Chart for NASDAQ:OXFD

Receive News & Stock Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related stocks with our FREE daily email newsletter.